News Scan for Nov 10, 2015

News brief

Hawaii reports 4 more dengue cases, 27 total

The Hawaii Department of Health (HDOH) yesterday confirmed that the number of locally acquired cases of dengue fever has increased by 4 since Nov 6, to 27, with potential exposure areas all across the big island of Hawaii.

Nineteen of the patients are Hawaiians, while 8 visitors have also been infected, the HDOH said in an update. All but 2 patients are adults, and all are recovering. Illness-onset dates range from Sep 15 to Nov 2. An HDOH map shows that cases reported eight potential exposure areas all across the island.

The agency said in the update, "HDOH continues to routinely monitor for cases of imported dengue infection on ALL islands and will continue to have Vector Control perform mosquito site assessments and abatement as needed. 

"Since the beginning of our current investigation on Hawaii island, one imported dengue fever case has been confirmed (on Oahu). This case is not associated with the Hawaii island investigation."

State Epidemiologist Sarah Park, MD, said, "Unfortunately, sometimes we have a situation where we're sort of behind the eight ball, frankly, which happened here," according to a story yesterday from Hawaii News Now.
Nov 9 HDOH update
Nov 9 Hawaii News Now story
Nov 9 CIDRAP News scan on previous update

 

CSL: Flu vaccine unit created by Novartis merger now called Seqirus

Australia-based drug manufacturer CSL Limited announced yesterday that its flu vaccines business is now called Seqirus, following the merger of Novartis's influenza unit—acquired on Jul 31—with CSL's vaccines and pharmaceutical business, bioCSL.

Seqirus ranks number two worldwide in flu vaccine sales, at $4 billion, with operations in more than 20 countries, the company said in a press release. Based in Maidenhead, United Kingdom, Seqirus provides pandemic and pre-pandemic vaccines and operates flu vaccine manufacturing in North America, Europe, and Australia.

Seqirus is derived from the phrase "securing health for all of us," the company said. In Canada, Spain, Germany, and Argentina, the flu vaccines division of Novartis will continue to be operated by Novartis until CSL can obtain local regulatory approvals, if required.
Nov 9 CSL press release

Coronavirus Scan for Nov 10, 2015

News brief

Riyadh science center, Saudi ministries launch MERS research effort

The King Abdulaziz City for Science and Technology (KACST) and Saudi Arabia's ministries of health and agriculture have launched a joint program for comprehensive MERS-CoV research on the Middle East, Arab News reported today as the country's Ministry of Health (MOH) reported no MERS cases for the 7th straight day.

KACST Director Prince Turki bin Saud bin Mohammed Al Saud said that, under the agreement, KACST will provide technical and financial support to conduct research on MERS-CoV (Middle East respiratory syndrome coronavirus) and spearhead the creation of a national database for the virus that will subsequently include all infectious diseases.

Involvement of Saudi universities in the research will also be sought, the story said.

So far MERS-CoV has sickened 1,275 people in Saudi Arabia since 2012, 546 of whom have died, the MOH said in today's update. In the past 7 days, the agency has reported that 4 people have recovered from the disease and 2 have died; 4 patients are still receiving treatment. The most recent case, reported on Nov 3, was in Riyadh.
Nov 10 Arab News story
Nov 10 MOH update

 

SARS-like bat coronavirus able to jump to humans, researchers say

A coronavirus closely related to the SARS (severe acute respiratory syndrome) virus appears able to infect human lung cells and jump from bats to people without mutation, according to a study yesterday in Nature Medicine.

University of North Carolina (UNC) researchers inserted the spike protein of a coronavirus found in horseshoe bats in China—called SHC014—into a SARS virus. They then determined in a lab dish that the hybrid virus the virus can latch on to the same human and bat receptor for entry, which shows it is able to jump from bats to people.

The virus also replicated as well as SARS-CoV in primary human airway cells in the lung, the preferred target for infection. The hybrid virus also replicated well in the lungs of mice that were susceptible to SARS.

SARS first jumped from animals to humans in 2002 and caused a worldwide outbreak, resulting in more than 8,000 cases and almost 800 deaths.

"This [SHC014] virus is highly pathogenic and treatments developed against the original SARS virus in 2002 and the ZMapp drugs used to fight Ebola fail to neutralize and control this particular virus," said senior author Ralph Baric, PhD, in a UNC press release today. "So building resources, rather than limiting them, to both examine animal populations for new threats and develop therapeutics is key for limiting future outbreaks."
Nov 9 Nat Med study
Nov 10 UNC press release

 

Study shows copper surfaces rapidly kill human coronavirus

Surfaces made of copper and copper alloys can inactivate a human coronavirus within minutes—as opposed to days for other surfaces—showing potential to combat MERS-CoV and other respiratory viruses, University of Southampton researchers reported today in mBio.

The team studied 229E, a human coronavirus closely related to MERS and SARS viruses that can cause disease ranging from the common cold to pneumonia. The virus remained infectious for at least 5 days on a range of common surfaces, such as stainless steel, Teflon, PVC, ceramic, glass, and silicone.

On a range of copper alloys, however, 229E was inactivated within a few minutes for a dose that simulated fingertip contamination. "Exposure to copper destroyed the viral genomes and irreversibly affected virus morphology, including disintegration of envelope and dispersal of surface spikes," the author wrote.

Bill Keevil, PhD, one of the study authors, said in a University of Southampton news release, "The rapid inactivation and irreversible destruction of the virus observed on copper and copper alloy surfaces suggests that the incorporation of copper alloy surfaces—in conjunction with effective cleaning regimes and good clinical practice—could help control transmission of these viruses."
Nov 10 mBio study
Nov 10 University of Southampton news release

This week's top reads